Omeros Corporation

OMER

Held by 2 specialist biotech funds

High short interest · No specialist buying

2 funds opened new positions. Next phase2 readout (Biological: narsoplimab): Dec 2025. Short interest: 22.8% of float.

BiotechnologyCEO: Gregory A. DemopulosIPO: 2009Website ↗

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Catalysts

Phase 2PositiveQ1 2009OMS302Cataract ExtractionNCT00721695

Primary: Pupil diameter (Day of Surgery)Enrollment:60/60Sites: 4RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ2 2009OMS103HPPostoperative PainNCT00624845

Primary: The primary efficacy endpoint is the mean VAS at 24 hours postoperatively. (24 hours)Enrollment:Target 200Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2010OMS103HPAnterior Cruciate Ligament ReconstructionNCT00245271

Primary: The overall incidence of adverse events regardless of relationship to study drug. (90 days)Enrollment:Target 480Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2010OMS103HPKnee InjuriesNCT00226772

Primary: Improvement in knee function (30 days)Enrollment:326/326Sites: 18RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2010OMS103HPKnee InjuriesNCT00226759

Primary: Improvement in knee function (30 days)Enrollment:321/321Sites: 20RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2010OMS201Urinary Calculi, Urinary Stones, Urinary Tract StonesNCT00857090

Primary: Peak systemic exposure. (Day of surgery)Enrollment:18/18Sites: 4RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2011OMS302 SolutionCataractNCT01193127

Primary: Pupil Diameter (mm) During Surgery (During surgery (immediately prior to surgical incision to wound closure))Enrollment:223/223Sites: 24RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2012OMS302Intraocular Lens ReplacementNCT01454063

Primary: Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery (from surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure))Enrollment:405/405Sites: 16RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2012OMS103HP-SMeniscal TearNCT01406561

Primary: KOOS Symptoms Subscale (30 days)Enrollment:344/344Sites: 18RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2012OMS302Intraocular Lens ReplacementNCT01579565

Primary: Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery (From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure))Enrollment:416/416Sites: 14RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2014OMS643762SchizophreniaNCT01952132

Primary: Safety (14 days)Enrollment:40/40Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ3 2014Part 1 OMS302Intraocular Lens Replacement, Intraoperative Floppy Iris SyndromeNCT02093689

Primary: Change in Pupil Diameter (Intraoperative)Enrollment:18/18Sites: 2NON_RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ4 2014OMS643762Huntington's DiseaseNCT02074410

Primary: Assess the Safety of OMS643762 (28 days)Enrollment:22/22Sites: 9RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2016OMS302Unilateral Cataract Extraction, Congenital CataractNCT02132312

Primary: Intraoperative Pupil Diameter (From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure), the mean time of surgery duration is 35.46 minutes with a standard deviation of 19.98.)Enrollment:78/78Sites: 11RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2020OMS721Thrombotic MicroangiopathiesNCT02222545

Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA (Day 1 to 37 days after end of treatment, approximately up to 31 weeks.)Enrollment:58/58Sites: 24NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2020OMS721 (narsoplimab)Ig AN, LN, MNNCT02682407

Primary: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). (up to 104 weeks)Enrollment:31/31Sites: 12RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ1 2021OMS721 (narsoplimab)Thrombotic Microangiopathies, Atypical Hemolytic Uremic SyndromeNCT03205995

Primary: Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26 (Week 26)Enrollment:6/6Sites: 4NA, TREATMENT

Phase 3NegativeQ1 2024OMS721Ig A NephropathyNCT03608033

Phase 2Q4 2024OMS906Paroxysmal Nocturnal HemoglobinuriaNCT05972967

Phase 2Q4 2025Biological: narsoplimabThrombotic Microangiopathies, Hematopoietic Stem Cell TransplantationNCT05855083

Phase 2Q1 2026OMS906 study drugC3 Glomerulopathy, Idiopathic Immune Complex-Mediated GlomerulonephritisNCT06209736

Phase 2Q4 2026OMS906 study drugParoxysmal Nocturnal HemoglobinuriaNCT06298955

Omeros Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research